Anika Therapeutics Inc (ANIK)
Healthcare
Drug Manufacturers - Specialty & Generic
19.30 $
+6.7%
vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Anika Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Breakout & Setup
Momentum & Trend
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Basics
Market Cap
The value of the entire company on the market: share price times total shares outstanding.
0.3$B
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
13Mio.
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
84.2%
Beta
Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.
0.2
Performance
Perf. 1M
Price performance over the last month.
0.70%
Perf. 3M
Price performance over the last 3 months.
5.10%
Perf. 6M
Price performance over the last 6 months.
58.30%
YTD Performance (%)
Price performance since the start of the year (Year to Date).
51.80%
52-Week-High Distance
How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high.
-10.0%
Perf. 1Y
Price performance over the last 12 months.
34.89%
Perf. 3Y
Price performance over the last 3 years.
-45.20%
Perf. 5Y
Price performance over the last 5 years.
-67.07%
Valuation
P/E
Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.
–
Forward P/E
P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future.
37.5
PEG
P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.
3.7
P/B
Price-to-book ratio: market value relative to book equity.
1.9
P/S
Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.
2.1
EV/EBITDA
Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero.
8.2
Price/FCF
Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.
420.0
Profitability
Gross Margin
Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power.
58.6%
EBIT Margin
EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.
–
Net Margin
Net margin: what's left of sales as profit after ALL costs, interest, and taxes.
-9.5%
Return on Equity
Return on equity: how much profit does the company generate per year on shareholders' equity?
-7.9%
Return on Assets
Return on assets: how much profit the company generates from its total assets (equity and debt combined).
-4.1%
Balance Sheet & Safety
Equity Ratio
Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.
–
Debt/Equity
Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity.
0.2
fortress balance sheet
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
9.62
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
3 out of 9
Growth
Sales Growth Last Quarter
Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY).
13.20%
EPS Growth Last Quarter
Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY).
-50.50%
Sales Growth (Year)
Sales growth in the last fiscal year versus the year before.
-5.91%
Forward Sales Growth
Sales growth analysts expect over the next 12 months — an estimate, not a guarantee.
6.72%
Forward EPS Growth
Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.
12.20%
Dividend
This stock currently pays no dividend.
Quality & Screener
Stage
Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line.
2
RS Rating
Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks.
75
EPS Rating
Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth.
14
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
3 out of 9
Fundamental Rating
Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below.
C (51 out of 100)
fortress balance sheet
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
9.62
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
Current Price
19.30 $
Price Target (average)
17.50 $
The price target sits 9.3% below the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.49 | – | -1 | -103.00 | – | 2 | 0 |
| 2025: Q1 | -0.34 | – | 26 | -35.40 | -18.60 | 0 | -3 |
| 2025: Q2 | -0.28 | – | 28 | -8.20 | -14.10 | 0 | -2 |
| 2025: Q3 | -0.16 | – | 28 | -28.20 | -8.40 | 7 | 5 |
| 2025: Q4 | 0.02 | – | 31 | – | 1.00 | 5 | 4 |
| 2026: Q1 | -0.37 | – | 30 | 13.20 | -17.10 | -5 | -6 |
| 2026: Q2 | 0.24 | 185.70 | 33 | 15.60 | 10.10 | -1 | -2 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Anika Therapeutics, Inc. , a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally.
| Employees | 235 |
|---|---|
| Headquarters | Bedford, MA |
| Website | anika.com |
| IPO Date | 29. Apr 1993 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Cheryl Renee Blanchard Ph.D. | Executive Chair | 1964 |
| Stephen D. Griffin | President, Principal Financial Officer, CEO & Director | 1986 |
| Ian W. McLeod | Senior VP, Chief Accounting Officer & Treasurer | 1966 |
| Matthew Hall | Executive Director of Corporate Development & Investor Relations | – |
| James Chase | Senior VP of International Sales & Marketing | – |
| Ben Joseph | VP of Commercial & Corporate Development | – |
| Lisa Funiciello | VP & Chief Human Resources Officer | – |
| Mira Leiwant | Senior Vice President of Regulatory, Quality & Clinical Affairs | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.